(HealthDay)—Four in 10 transgender women have HIV, which shows the urgent need to offer them more prevention and treatment services, according to a new U.S. Centers for Disease Control and Prevention report.
Apr 16, 2021
0
193
Anti-retroviral drugs are a vital tool in the prevention and treatment of HIV. A new study of pregnant women in Tanzania shows that life-long antiviral treatment also seems to prevent viral transmission from mother to baby. ...
Feb 11, 2021
0
8
Universal HIV testing with linkage to treatment and prevention may be a promising approach to accelerate reductions in new infections in generalized epidemic settings, according to a study published February 9th, 2021 in ...
Feb 9, 2021
0
0
An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition ...
Jan 27, 2021
0
9
When taken daily, pre-exposure prophylaxis, or PrEP, is a highly effective way to prevent HIV transmission, according to the Centers for Disease Control and Prevention. Now a new study shows that implementing PrEP distribution ...
Dec 16, 2020
0
2
Healthy Lactobacillus bacteria in the vagina are critical for women's health, but the accumulation of additional bacterial genera can imbalance the vaginal ecosystem. Such an imbalance may result in bacterial metabolism of ...
Dec 3, 2020
0
9
The nonprofit International Partnership for Microbicides (IPM) is pleased to announce the World Health Organization's (WHO) prequalification of the dapivirine ring, a monthly vaginal ring to reduce women's HIV risk.
Nov 30, 2020
0
3
New HIV data, released today by the Kirby Institute at UNSW Sydney for World AIDS Day, are a reminder for Australia to sustain its efforts in HIV prevention amidst the COVID-19 pandemic.
Nov 30, 2020
0
4
Early unblinding of the of long-acting cabotegravir (CAB LA) is a milestone for prevention of HIV among women in sub Saharan Africa.
Nov 10, 2020
0
6
A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among ...
Jul 7, 2020
0
1
